Log in
Register
Search
Search titles only
By:
Search titles only
By:
Forums
New posts
Forum list
Search forums
Leaderboards
Games
Our Blog
Blogs
New entries
New comments
Blog list
Search blogs
Credits
Transactions
Shop
Blessings: ✟0.00
Tickets
Open new ticket
Watched
Donate
Log in
Register
Search
Search titles only
By:
Search titles only
By:
More options
Toggle width
Share this page
Share this page
Share
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Menu
Install the app
Install
Forums
Discussion and Debate
Discussion and Debate
News & Current Events (Articles Required)
New Study Shows Puberty Blockers May Cause Permanent Harm
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="rjs330" data-source="post: 77651035" data-attributes="member: 377008"><p>The Cass report is pretty clear on the subject of puberty blockers and the transitioning of kids. The UK has left the the US behind. Hopefully we'll catch up to the rest of the world.</p><p> <a href="https://www.theatlantic.com/ideas/archive/2024/04/cass-report-youth-gender-medicine/678031/" target="_blank">https://www.theatlantic.com/ideas/archive/2024/04/cass-report-youth-gender-medicine/678031/</a></p><p></p><p>The Cass report says kids need a clinical approach. What does this mean exactly. Here's some information from the report. </p><p></p><p>While a considerable amount of research has been published in this field, systematic evidence reviews demonstrated the poor quality of the published studies, meaning there is not a reliable evidence base upon which to make clinical decisions, or for children and their families to make informed choices.</p><p></p><p>The strengths and weaknesses of the evidence base on the care of children and young people are often misrepresented and overstated, both in scientific publications and social debate.</p><p></p><p>The rationale for early puberty suppression remains unclear, with weak evidence regarding the impact on gender dysphoria, mental or psychosocial health. The effect on cognitive and psychosexual development remains unknown.</p><p></p><p>The use of masculinising / feminising hormones in those under the age of 18 also presents many unknowns, despite their longstanding use in the adult transgender population. The lack of long-term follow-up data on those commencing treatment at an earlier age means we have inadequate information about the range of outcomes for this group. </p><p></p><p>Clinicians are unable to determine with any certainty which children and young people will go on to have an enduring trans identity. </p><p></p><p>For most young people, a medical pathway will not be the best way to manage their gender-related distress. For those young people for whom a medical pathway is clinically indicated, it is not enough to provide this without also addressing wider mental health and/or psychosocially challenging problems. </p><p></p><p>The puberty blocker trial previously announced by NHS England should be part of a programme of research which also evaluates outcomes of psychosocial interventions and masculinising/ feminising hormones.</p><p></p><p>The option to provide masculinising/feminising hormones from age 16 is available, but the Review recommends extreme caution. There should be a clear clinical rationale for providing hormones at this stage rather than waiting until an individual reaches 18. Every case considered for medical treatment should be discussed at a national Multi- Disciplinary Team (MDT). </p><p></p><p></p><p>All these things are NOT being done in the US. Should they be?</p></blockquote><p></p>
[QUOTE="rjs330, post: 77651035, member: 377008"] The Cass report is pretty clear on the subject of puberty blockers and the transitioning of kids. The UK has left the the US behind. Hopefully we'll catch up to the rest of the world. [URL]https://www.theatlantic.com/ideas/archive/2024/04/cass-report-youth-gender-medicine/678031/[/URL] The Cass report says kids need a clinical approach. What does this mean exactly. Here's some information from the report. While a considerable amount of research has been published in this field, systematic evidence reviews demonstrated the poor quality of the published studies, meaning there is not a reliable evidence base upon which to make clinical decisions, or for children and their families to make informed choices. The strengths and weaknesses of the evidence base on the care of children and young people are often misrepresented and overstated, both in scientific publications and social debate. The rationale for early puberty suppression remains unclear, with weak evidence regarding the impact on gender dysphoria, mental or psychosocial health. The effect on cognitive and psychosexual development remains unknown. The use of masculinising / feminising hormones in those under the age of 18 also presents many unknowns, despite their longstanding use in the adult transgender population. The lack of long-term follow-up data on those commencing treatment at an earlier age means we have inadequate information about the range of outcomes for this group. Clinicians are unable to determine with any certainty which children and young people will go on to have an enduring trans identity. For most young people, a medical pathway will not be the best way to manage their gender-related distress. For those young people for whom a medical pathway is clinically indicated, it is not enough to provide this without also addressing wider mental health and/or psychosocially challenging problems. The puberty blocker trial previously announced by NHS England should be part of a programme of research which also evaluates outcomes of psychosocial interventions and masculinising/ feminising hormones. The option to provide masculinising/feminising hormones from age 16 is available, but the Review recommends extreme caution. There should be a clear clinical rationale for providing hormones at this stage rather than waiting until an individual reaches 18. Every case considered for medical treatment should be discussed at a national Multi- Disciplinary Team (MDT). All these things are NOT being done in the US. Should they be? [/QUOTE]
Insert quotes…
Verification
Post reply
Forums
Discussion and Debate
Discussion and Debate
News & Current Events (Articles Required)
New Study Shows Puberty Blockers May Cause Permanent Harm
Top
Bottom